FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308026449> ?p ?o ?g. }

• W4308026449 endingPage "e002417" @default.
• W4308026449 startingPage "e002417" @default.
• W4308026449 abstract "Objectives Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMID) following two vaccine doses. To protect these vulnerable patients against severe COVID-19 disease, a three-dose primary vaccination strategy has been implemented in many countries. The aim of this study was to evaluate humoral response and safety of primary vaccination with three doses in patients with IMID. Methods Patients with IMID on immunosuppressive therapy and healthy controls receiving three-dose and two-dose primary SARS-CoV-2 vaccination, respectively, were included in this prospective observational cohort study. Anti-Spike antibodies were assessed 2–4 weeks, and 12 weeks following each dose. The main outcome was anti-Spike antibody levels 2–4 weeks following three doses in patients with IMID and two doses in controls. Additional outcomes were the antibody decline rate and adverse events. Results 1100 patients and 303 controls were included. Following three-dose vaccination, patients achieved median (IQR) antibody levels of 5720 BAU/mL (2138–8732) compared with 4495 (1591–6639) in controls receiving two doses, p=0.27. Anti-Spike antibody levels increased with median 1932 BAU/mL (IQR 150–4978) after the third dose. The interval between the vaccine doses and vaccination with mRNA-1273 or a combination of vaccines were associated with antibody levels following the third dose. Antibody levels had a slower decline-rate following the third than the second vaccine dose, p<0.001. Adverse events were reported by 464 (47%) patients and by 196 (78%) controls. Disease flares were reported by 70 (7%) patients. Conclusions This study shows that additional vaccine doses to patients with IMID contribute to strong and sustained immune-responses comparable to healthy persons vaccinated twice, and supports repeated vaccination of patients with IMID. Trial registration number NCT04798625 ." @default.
• W4308026449 created "2022-11-07" @default.
• W4308026449 creator A5008586750 @default.
• W4308026449 creator A5011957275 @default.
• W4308026449 creator A5018708728 @default.
• W4308026449 creator A5025438429 @default.
• W4308026449 creator A5026747664 @default.
• W4308026449 creator A5029345620 @default.
• W4308026449 creator A5033823447 @default.
• W4308026449 creator A5035671675 @default.
• W4308026449 creator A5037227826 @default.
• W4308026449 creator A5039187353 @default.
• W4308026449 creator A5046032682 @default.
• W4308026449 creator A5059000621 @default.
• W4308026449 creator A5064983192 @default.
• W4308026449 creator A5070289679 @default.
• W4308026449 creator A5072837330 @default.
• W4308026449 creator A5076820474 @default.
• W4308026449 creator A5077105911 @default.
• W4308026449 creator A5079962813 @default.
• W4308026449 creator A5085955224 @default.
• W4308026449 creator A5087580445 @default.
• W4308026449 date "2022-11-01" @default.
• W4308026449 modified "2023-10-13" @default.
• W4308026449 title "Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy" @default.
• W4308026449 cites W2140073887 @default.
• W4308026449 cites W2230558734 @default.
• W4308026449 cites W3028098130 @default.
• W4308026449 cites W3094105410 @default.
• W4308026449 cites W3108610942 @default.
• W4308026449 cites W3111255098 @default.
• W4308026449 cites W3116076159 @default.
• W4308026449 cites W3121562869 @default.
• W4308026449 cites W3163785571 @default.
• W4308026449 cites W3163971529 @default.
• W4308026449 cites W3164008218 @default.
• W4308026449 cites W3164069651 @default.
• W4308026449 cites W3180511106 @default.
• W4308026449 cites W3184172540 @default.
• W4308026449 cites W3192305430 @default.
• W4308026449 cites W3196356596 @default.
• W4308026449 cites W3196397911 @default.
• W4308026449 cites W3198017567 @default.
• W4308026449 cites W3202826390 @default.
• W4308026449 cites W3216473757 @default.
• W4308026449 cites W3217661335 @default.
• W4308026449 cites W4205283268 @default.
• W4308026449 cites W4205483821 @default.
• W4308026449 cites W4206069935 @default.
• W4308026449 cites W4210343424 @default.
• W4308026449 cites W4210747912 @default.
• W4308026449 cites W4214933591 @default.
• W4308026449 cites W4220774929 @default.
• W4308026449 cites W4224942813 @default.
• W4308026449 cites W4225368559 @default.
• W4308026449 cites W4225413377 @default.
• W4308026449 cites W4225470021 @default.
• W4308026449 cites W4225854071 @default.
• W4308026449 cites W4226183218 @default.
• W4308026449 cites W4291818587 @default.
• W4308026449 cites W4302026744 @default.
• W4308026449 doi "https://doi.org/10.1136/rmdopen-2022-002417" @default.
• W4308026449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328399" @default.
• W4308026449 hasPublicationYear "2022" @default.
• W4308026449 type Work @default.
• W4308026449 citedByCount "8" @default.
• W4308026449 countsByYear W43080264492023 @default.
• W4308026449 crossrefType "journal-article" @default.
• W4308026449 hasAuthorship W4308026449A5008586750 @default.
• W4308026449 hasAuthorship W4308026449A5011957275 @default.
• W4308026449 hasAuthorship W4308026449A5018708728 @default.
• W4308026449 hasAuthorship W4308026449A5025438429 @default.
• W4308026449 hasAuthorship W4308026449A5026747664 @default.
• W4308026449 hasAuthorship W4308026449A5029345620 @default.
• W4308026449 hasAuthorship W4308026449A5033823447 @default.
• W4308026449 hasAuthorship W4308026449A5035671675 @default.
• W4308026449 hasAuthorship W4308026449A5037227826 @default.
• W4308026449 hasAuthorship W4308026449A5039187353 @default.
• W4308026449 hasAuthorship W4308026449A5046032682 @default.
• W4308026449 hasAuthorship W4308026449A5059000621 @default.
• W4308026449 hasAuthorship W4308026449A5064983192 @default.
• W4308026449 hasAuthorship W4308026449A5070289679 @default.
• W4308026449 hasAuthorship W4308026449A5072837330 @default.
• W4308026449 hasAuthorship W4308026449A5076820474 @default.
• W4308026449 hasAuthorship W4308026449A5077105911 @default.
• W4308026449 hasAuthorship W4308026449A5079962813 @default.
• W4308026449 hasAuthorship W4308026449A5085955224 @default.
• W4308026449 hasAuthorship W4308026449A5087580445 @default.
• W4308026449 hasBestOaLocation W43080264491 @default.
• W4308026449 hasConcept C126322002 @default.
• W4308026449 hasConcept C159654299 @default.
• W4308026449 hasConcept C197934379 @default.
• W4308026449 hasConcept C203014093 @default.
• W4308026449 hasConcept C22070199 @default.
• W4308026449 hasConcept C2780868878 @default.
• W4308026449 hasConcept C71924100 @default.
• W4308026449 hasConcept C8891405 @default.
• W4308026449 hasConceptScore W4308026449C126322002 @default.

• next